"TJl Education Support Scheme for Employees' Children" Marks 10th Year with Record Scholarships Awarded

"TJl Education Support Scheme for Employees' Children" Marks 10th Year with Record Scholarships Awarded

HONG KONG, Jan. 21, 2026 /PRNewswire/ -- Tam Jai International Co. Limited ("TJI" or the "Company", together with its subsidiaries, the "Group"), one of the leading and renowned restaurant groups in Hong Kong, granted over HK$1.6 million in...

Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease

Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease

SHANGHAI, Jan. 15, 2026 /PRNewswire/ -- AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has accepted its...

A New Era of Digital Innovation: Elitery Global Technology Sdn. Bhd. Granted Malaysia Digital (MD) Status

A New Era of Digital Innovation: Elitery Global Technology Sdn. Bhd. Granted Malaysia Digital (MD) Status

KUALA LUMPUR, Malaysia, Jan. 12, 2026 /PRNewswire/ -- Elitery Global Technology Sdn. Bhd., a subsidiary of PT Data Sinergitama Jaya Tbk, proudly announces that it has been awarded the prestigious Malaysia Digital (MD) Status by the Malaysia Digital...

Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA

Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA

CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally...

Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC

Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC

CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also...

SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Gastric Cancer.

SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Gastric Cancer.

SEONGNAM, South Korea, Dec. 24, 2025 /PRNewswire/ -- SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101...

First The Generation Essentials Group-Sponsored SPAC Announces Successful Closing of $150 million IPO

First The Generation Essentials Group-Sponsored SPAC Announces Successful Closing of $150 million IPO

PARIS, NEW YORK and LONDON, Dec. 23, 2025 /PRNewswire/ -- TGE Value Creative Solutions Corp (the "Company"), a special purpose acquisition company sponsored by The Generation Essentials Group (NYSE: TGE; LSE: TGE), announced today that it...

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC

SUZHOU, China, Dec. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio...

Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases

Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases

SAN FRANCISCO, Dec. 16, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code: 2563.HK), today announced that the first patient has been dosed for one of its key oversea...

Aspire Announces Major Australia, EU and US Regulatory Milestones, Marking a New Chapter in Its Global Expansion

Aspire Announces Major Australia, EU and US Regulatory Milestones, Marking a New Chapter in Its Global Expansion

SINGAPORE, Dec. 16, 2025 /PRNewswire/ -- Aspire, the Singapore-headquartered fintech, today announced a series of regulatory milestones marking a major step in its global expansion. Over the past year alone, the company has secured eight licenses...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • menu
    menu